Insight Molecular Diagnostics Inc. — Director's Dealing 2024

May 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2024-05-20

Reporting Person: Riggs Josh (Director, CEO and President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-20	Option to Purchase Common Stock	$2.76	A	90000	Acquired	2034-05-20	Common Stock (90000)	Direct

Footnotes

F1: 25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date.